PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up

Nanomedicines based on poly(lactic-co-glycolic acid) (PLGA) carriers offer tremendous opportunities for biomedical research. Although several PLGA-based systems have already been approved by both the Food and Drug Administration (FDA) European Medicine Agency (EMA), are widely used in clinics treatment or diagnosis of diseases, no PLGA nanomedicine formulation is currently available global market. One most impeding barriers development a manufacturing technique that allows transfer production from laboratory to an industrial scale with proper characterization quality control methods. This review provides comprehensive overview technologies analysis polymeric nanomedicines nanoparticles, scale-up challenges hinder their applicability, issues associated successful translation into clinical practice.